Drug candidate is one of several oncology assets approaching or in clinical development, discovered through Oxford ...

Precision oncology has entered a new phase, as data sets mature and a new wave of tools emerges to help clinicians manage ...

Boehringer Ingelheim has breathed life into an American Lung Association campaign, providing support for a new push to ...

Results come after positive results from a trial among people with idiopathic pulmomary disease.

Boehringer Ingelheim Pharma GmbH & Co KG has selected a third oncology drug candidate to advance into IND-enabling studies under its ongoing collaboration with Oxford Biotherapeutics Ltd.

Sonelokimab, adalimumab, lutikizumab, and bimekizumab are the top-rated treatments for moderate-to-severe HS, a network ...

What happens when data projects forget the people who use them? A Disconnect. Boehringer Ingelheim turned things around by ...

Ipratropium Bromide Nasal Solution is a bioequivalent to Atrovent Nasal Sprayof Boehringer Ingelheim Pharmaceuticals, Inc.

The site was created by Boehringer Ingelheim after a survey identified knowledge gaps among owners on many health topics ...

The collaboration with Oxford BioTherapeutics complements Boehringer Ingelheim’s development of next-generation potentially life-changing cancer immunotherapies with the identification of ...